title: Current trends in molecular diagnostics of chronic myeloid leukemia.
abstract: Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.
authors.affiliation: a Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, UCIBIO , Universidade Nova de Lisboa , Caparica , Portugal.
authors.forename: Raquel
authors.initials: R
authors.lastname: Vinhas
authors.affiliation: a Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, UCIBIO , Universidade Nova de Lisboa , Caparica , Portugal.
authors.forename: Milton
authors.initials: M
authors.lastname: Cordeiro
authors.affiliation: a Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, UCIBIO , Universidade Nova de Lisboa , Caparica , Portugal.
authors.forename: Pedro
authors.initials: P
authors.lastname: Pedrosa
authors.affiliation: a Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, UCIBIO , Universidade Nova de Lisboa , Caparica , Portugal.
authors.forename: Alexandra R
authors.initials: AR
authors.lastname: Fernandes
authors.affiliation: a Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, UCIBIO , Universidade Nova de Lisboa , Caparica , Portugal.
authors.forename: Pedro V
authors.initials: PV
authors.lastname: Baptista
mesh_terms: D014408:Biomarkers, Tumor; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D025202:Molecular Diagnostic Techniques / Q000379:methods; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D014178:Translocation, Genetic
chemical_list: D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl
keywords: Chronic myeloid leukemia; molecular diagnostics; nanotheranostics; precision medicine